Calidi Biotherapeutics (CLDI) Change in Account Payables (2022 - 2025)
Calidi Biotherapeutics (CLDI) posted quarterly Change in Account Payables of -$404000.0 for Q4 2025, up 65.32% year-over-year from -$244371.8 in Q4 2024, and down 111.52% quarter-over-quarter from -$191000.0 in Q3 2025.
Calidi Biotherapeutics (CLDI) Change in Account Payables (2022 - 2025) Analysis & Trends
Calidi Biotherapeutics' Change in Account Payables history runs 4 years deep, the most recent figure standing at -$404000.0 for Q4 2025.
- In Q4 2025, Change in Account Payables rose 65.32% year-over-year to -$404000.0; the TTM figure through Dec 2025 stood at -$1.3 million (down 111.46% YoY), while the FY2025 annual figure was -$1.3 million, down 111.46% from the prior year.
- Change in Account Payables for Q4 2025 stood at -$404000.0, down from -$191000.0 in the prior quarter.
- The five-year high for Change in Account Payables was $1.6 million in Q3 2022, with the low at -$6.0 million in Q3 2023.
- The 4-year median for Change in Account Payables is -$647.5 (2022), against an average of -$406375.0.
- The sharpest annual moves came in 2023 and 2024: Change in Account Payables tumbled 315958.21% in 2023, then surged 4509.52% in 2024.
- Calidi Biotherapeutics' Change in Account Payables stood at $62000.0 in 2022, then soared by 2295.16% to $1.5 million in 2023, then tumbled by 178.45% to -$1.2 million in 2024, then surged by 65.32% to -$404000.0 in 2025.
- Business Quant data shows CLDI's Change in Account Payables at -$404000.0 in Q4 2025, -$191000.0 in Q3 2025, and $19000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Calidi Biotherapeutics | 1.88 Mn | -2.22 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -404,000.00 |
| Dec 31, 2025 | -404,000.00 |
| Sep 30, 2025 | -191,000.00 |
| Sep 30, 2025 | -191,000.00 |
| Jun 30, 2025 | 19,000.00 |
| Jun 30, 2025 | 19,000.00 |
| Mar 31, 2025 | -752,000.00 |
| Mar 31, 2025 | -752,000.00 |
| Dec 31, 2024 | -1.17 Mn |
| Dec 31, 2024 | -1.17 Mn |
| Sep 30, 2024 | -605,000.00 |
| Sep 30, 2024 | -605,000.00 |
| Jun 30, 2024 | 174,000.00 |
| Jun 30, 2024 | 174,000.00 |
| Mar 31, 2024 | 968,000.00 |
| Mar 31, 2024 | 968,000.00 |
| Dec 31, 2023 | 1.49 Mn |
| Dec 31, 2023 | 1.49 Mn |
| Sep 30, 2023 | -5.98 Mn |
| Sep 30, 2023 | -5.98 Mn |